HRP20050933A2 - Organic compounds - Google Patents

Organic compounds

Info

Publication number
HRP20050933A2
HRP20050933A2 HR20050933A HRP20050933A HRP20050933A2 HR P20050933 A2 HRP20050933 A2 HR P20050933A2 HR 20050933 A HR20050933 A HR 20050933A HR P20050933 A HRP20050933 A HR P20050933A HR P20050933 A2 HRP20050933 A2 HR P20050933A2
Authority
HR
Croatia
Prior art keywords
organic compounds
compounds
zwitterions
muscarinic
receptor
Prior art date
Application number
HR20050933A
Other languages
English (en)
Croatian (hr)
Inventor
Paul Collingwood Stephen
Cox Brian
Baettig Urs
Bhalay Gurdip
James Devereux Nicholas
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33420896&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20050933(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0324887A external-priority patent/GB0324887D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HRP20050933A2 publication Critical patent/HRP20050933A2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
HR20050933A 2003-05-02 2005-10-28 Organic compounds HRP20050933A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0310232 2003-05-02
GB0324887A GB0324887D0 (en) 2003-10-24 2003-10-24 Organic compounds
PCT/EP2004/004605 WO2004096800A2 (en) 2003-05-02 2004-04-30 Quinuclidine derivatives binding to mucarinic m3 receptors

Publications (1)

Publication Number Publication Date
HRP20050933A2 true HRP20050933A2 (en) 2006-12-31

Family

ID=33420896

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20050933A HRP20050933A2 (en) 2003-05-02 2005-10-28 Organic compounds

Country Status (32)

Country Link
US (2) US20070060563A1 (es)
EP (1) EP1631569B1 (es)
JP (1) JP4416786B2 (es)
KR (1) KR100896544B1 (es)
AR (1) AR044134A1 (es)
AT (1) ATE440840T1 (es)
AU (1) AU2004234069B2 (es)
BR (1) BRPI0410238A (es)
CA (1) CA2523436C (es)
CL (1) CL2004000918A1 (es)
CO (1) CO5700782A2 (es)
CY (1) CY1109655T1 (es)
DE (1) DE602004022805D1 (es)
DK (1) DK1631569T3 (es)
EC (1) ECSP056134A (es)
ES (1) ES2331185T3 (es)
HK (1) HK1087704A1 (es)
HR (1) HRP20050933A2 (es)
IL (1) IL171591A (es)
IS (1) IS2746B (es)
MA (1) MA27775A1 (es)
MX (1) MXPA05011739A (es)
MY (1) MY142652A (es)
NO (1) NO20055688L (es)
NZ (1) NZ542995A (es)
PE (1) PE20050465A1 (es)
PL (1) PL1631569T3 (es)
PT (1) PT1631569E (es)
RU (1) RU2363700C2 (es)
SI (1) SI1631569T1 (es)
TW (1) TWI340139B (es)
WO (1) WO2004096800A2 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2239546B1 (es) * 2004-03-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos esteres de quinuclidina cuaternizados.
GB0410712D0 (en) 2004-05-13 2004-06-16 Novartis Ag Organic compounds
GB0424284D0 (en) * 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0428416D0 (en) 2004-12-24 2005-02-02 Novartis Ag Organic compounds
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
EP1900737A1 (en) * 2006-08-31 2008-03-19 Novartis AG Polymorph of (R)-3-(2-hydroxy-2,2-diphenyl-acetoxy)-1-(isoxazol-3-ylcarbamoyl-methyl)-1-azonia-bicyclo-[2.2.2]octane bromide
EP1894568A1 (en) * 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
ATE555111T1 (de) * 2006-12-19 2012-05-15 Astrazeneca Ab Chinuclidinol-derivate als muscarinrezeptor- antagonisten
EP1950196A1 (de) * 2007-01-29 2008-07-30 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Herstellung von Ammoniumhexafluorophosphaten
CA2697752C (en) 2007-09-07 2016-01-26 Theravance, Inc. Guanidine-containing compounds useful as muscarinic receptor antagonists
EP2222637A1 (en) 2007-12-14 2010-09-01 Theravance, Inc. Amidine-containing compounds useful as muscarinic receptor antagonists
ES2442930T3 (es) 2008-01-11 2014-02-14 Novartis Ag Pirimidinas como inhibidores de cinasas
CN102089304A (zh) 2008-05-13 2011-06-08 阿斯利康(瑞典)有限公司 作为m3毒蕈碱性受体拮抗剂的奎宁环衍生物
GB0808709D0 (en) * 2008-05-13 2008-06-18 Astrazeneca Ab New combination 295
EP2315589A4 (en) * 2008-05-13 2013-09-11 Astrazeneca Ab PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A beta2-ADRENOCEPTOR AGONIST
US20090326004A1 (en) 2008-06-03 2009-12-31 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
GB0811100D0 (en) * 2008-06-17 2008-07-23 Astrazeneca Ab New combination
WO2009153536A1 (en) * 2008-06-17 2009-12-23 Argenta Discovery Limited 1-aza-bicyclo [2.2.2] octane derivatives useful as muscarinic receptor antagonists
WO2011161018A1 (en) * 2010-06-22 2011-12-29 Chiesi Farmaceutici S.P.A. Alkaloid aminoester derivatives and medicinal compositions thereof
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
CA2828219A1 (en) 2011-02-25 2012-08-30 Irm Llc Pyrazolo [1,5-a] pyridines as trk inhibitors
JP2011195593A (ja) * 2011-06-30 2011-10-06 Astrazeneca Ab ムスカリンｍ３受容体アンタゴニストとしてのキヌクリジン誘導体
RU2628082C2 (ru) * 2011-12-30 2017-08-14 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Хинуклидиновые эфиры 1-азагетероциклилуксусной кислоты в качестве антимускариновых средств, способ их получения и их лекарственные композиции
EP2844251B1 (en) 2012-05-03 2018-08-01 Saint Louis College of Pharmacy Compositions and methods for increasing neurotrophic peptides
TWI647227B (zh) * 2013-02-28 2019-01-11 日商安斯泰來製藥股份有限公司 ２－醯胺噻唑衍生物或其鹽
CZ306791B6 (cs) 2013-10-29 2017-07-12 Zentiva, K.S. Průmyslově využitelný způsob přípravy aklidinium bromidu o vysoké čistotě
PT108370B (pt) * 2015-03-30 2018-10-25 Hovione Farm S A Processo de preparação de brometo de aclidínio
PL3111978T3 (pl) 2015-07-03 2022-01-24 Novartis Ag Inhalator przystosowany do odczytu informacji przechowywanych w środkach przechowywania danych pojemnika

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1219606A (en) * 1968-07-15 1971-01-20 Rech S Et D Applic Scient Soge Quinuclidinol derivatives and preparation thereof
DK534178A (da) * 1977-12-16 1979-06-17 Interx Research Corp Anticholinerge midler med sektrtionshaemmende virkning
ES2165768B1 (es) * 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
EP1302458A4 (en) * 2000-07-11 2005-10-19 Banyu Pharma Co Ltd ESTERDERIVATE
RU2282629C2 (ru) * 2000-12-28 2006-08-27 Альмиралль Продесфарма Аг Производные хинуклидина, способ их получения и фармацевтическая композиция на их основе
EA006505B1 (ru) * 2001-12-20 2005-12-29 Лабораториос С.А.Л.В.А.Т.,С.А. Производные карбамата 1-алкил-1-азониабицикло[2.2.2]октана и их применение в качестве антагонистов мускаринового рецептора
GB0424284D0 (en) * 2004-11-02 2004-12-01 Novartis Ag Organic compounds
EP1900737A1 (en) * 2006-08-31 2008-03-19 Novartis AG Polymorph of (R)-3-(2-hydroxy-2,2-diphenyl-acetoxy)-1-(isoxazol-3-ylcarbamoyl-methyl)-1-azonia-bicyclo-[2.2.2]octane bromide

Also Published As

Publication number Publication date
CA2523436A1 (en) 2004-11-11
CO5700782A2 (es) 2006-11-30
ES2331185T3 (es) 2009-12-23
DE602004022805D1 (de) 2009-10-08
KR20060015572A (ko) 2006-02-17
MA27775A1 (fr) 2006-02-01
US20070060563A1 (en) 2007-03-15
JP4416786B2 (ja) 2010-02-17
DK1631569T3 (da) 2009-11-23
IS2746B (is) 2011-08-15
AU2004234069B2 (en) 2008-02-21
KR100896544B1 (ko) 2009-05-07
RU2363700C2 (ru) 2009-08-10
NO20055688L (no) 2006-01-09
EP1631569A2 (en) 2006-03-08
IS8158A (is) 2005-11-30
PE20050465A1 (es) 2005-07-18
US8168654B2 (en) 2012-05-01
BRPI0410238A (pt) 2006-05-16
WO2004096800A2 (en) 2004-11-11
HK1087704A1 (en) 2006-10-20
AR044134A1 (es) 2005-08-24
PT1631569E (pt) 2009-11-26
TWI340139B (en) 2011-04-11
NO20055688D0 (no) 2005-12-01
SI1631569T1 (sl) 2010-01-29
ATE440840T1 (de) 2009-09-15
TW200505920A (en) 2005-02-16
PL1631569T3 (pl) 2010-02-26
EP1631569B1 (en) 2009-08-26
ECSP056134A (es) 2006-04-19
CA2523436C (en) 2011-11-01
AU2004234069A1 (en) 2004-11-11
CY1109655T1 (el) 2014-08-13
CL2004000918A1 (es) 2005-02-11
RU2005137360A (ru) 2006-07-27
MY142652A (en) 2010-12-15
JP2006525267A (ja) 2006-11-09
WO2004096800A3 (en) 2005-01-06
IL171591A (en) 2010-11-30
US20100041887A1 (en) 2010-02-18
MXPA05011739A (es) 2006-01-26
NZ542995A (en) 2009-02-28

Similar Documents

Publication Publication Date Title
HRP20050933A2 (en) Organic compounds
DE602004011199D1 (de) 5-phenylthiazolderivate und deren verwendung als p13-kinase-inhibitoren
ECSP055676A (es) Piperazinas heterocíclicas sustituidas para el tratamiento de la esquizofrenia
ES2368594T3 (es) Derivados sustituidos de ciclohexilmetilo.
BRPI0519292A2 (pt) compostos orgÂnicos
MEP45308A (en) [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
TW200519106A (en) Organic compounds
ATE411296T1 (de) Imidazolinderivate mit cb1-antagonistischer wirkung
SE0401971D0 (sv) Piperidne derivatives
MEP36508A (en) Triazolopyrazine derivatives useful as anti-cancer agents
CY1112960T1 (el) Παραγωγα ουριας, μεθοδοι για την παρασκευη τους και χρησεις αυτων
BRPI0406762A (pt) Derivados de n-(1-benzil-2-oxo-2-(1-piperazinil)etil)-1-piperidincarb oxamida e compostos relacionados como antagonistas de cgrp, para tratamento de dores de cabeça
WO2007084595A3 (en) Carbocyclic and heterocyclic arylsulfones as gamma secretase inhibitors
ATE541839T1 (de) Pyrrolidiniumderivate als m3-muskarinische rezeptoren
ATE553095T1 (de) Neue imidazolderivate, deren herstellung und deren verwendung als intermediate zur herstellung von arzneimitteln und pestiziden
NO20081001L (no) Derivater av karboksamid som antagonister for muskarinisk reseptor
SE0403171D0 (sv) New compounds
ATE409179T1 (de) Tetralin- und indanderivate und deren anwendungen als 5-ht-antagonisten
SE0401970D0 (sv) Novel compounds
ATE543803T1 (de) 3-ä2-(3-azylamino-2-oxo-2h-pyridin-1- yl)acetylaminoü-4-oxopentansäurederivate und deren verwendung als caspase-inhibitoren
SE0302139D0 (sv) Novel compounds
WO2009055629A3 (en) Cyclohexeneamide derivatives and their use as trpv1 antagonist
SE0303541D0 (sv) New compounds
DE602004011204D1 (de) Quinoxalin-3-on-verdindungen als orexin-rezeptor antagonisten.
SE0303280D0 (sv) Novel compounds

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20110423

Year of fee payment: 8

OBST Application withdrawn